Expression of the novel tumour suppressor sterile alpha motif and HD domain-containing protein 1 is an independent adverse prognostic factor in classical Hodgkin lymphoma.
Ioanna XagorarisTheodoros P VassilakopoulosElias DrakosMaria K AngelopoulouFotios P PanitsasNikolas HeroldL Jeffrey MedeirosXanthoula GiakoumisGerassimos A PangalisGeorgios RassidakisPublished in: British journal of haematology (2021)
The expression patterns and prognostic significance of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) protein in the neoplastic Hodgkin and Reed Sternberg (HRS) cells of Hodgkin lymphoma (HL) were investigated in a cohort of 154 patients with HL treated with standard regimens. SAMHD1 expression was assessed by immunohistochemistry using diagnostic lymph node biopsies obtained prior to treatment. Using an arbitrary 20% cut-off, SAMHD1 was positive in HRS cells of 48/154 (31·2%) patients. SAMHD1 expression was not associated with clinicopathologic parameters, such as age, gender, stage or histologic subtype. In 125 patients with a median follow-up of 90 months (7-401 months), SAMHD1 expression in HRS cells significantly correlated with inferior freedom from progression (FFP) (P = 0·025), disease-specific survival (DSS) (P = 0·013) and overall survival (OS) (P = 0·01). Importantly, in multivariate models together with disease stage, histology subtype and type of treatment as covariates, SAMHD1 expression retained an independent significant association with unfavourable FFP (P = 0·005) as well as DSS (P = 0·022) and OS (P = 0·018). These findings uncover the significance of a novel, adverse prognostic factor in HL that may have therapeutic implications since SAMHD1 inhibitors are now available for clinical use.
Keyphrases
- poor prognosis
- prognostic factors
- hodgkin lymphoma
- binding protein
- induced apoptosis
- lymph node
- long non coding rna
- emergency department
- early stage
- oxidative stress
- signaling pathway
- ejection fraction
- radiation therapy
- end stage renal disease
- newly diagnosed
- amino acid
- free survival
- single molecule
- locally advanced
- patient reported